Sfoglia per Autore
Tipranavir (TPV) genotypic Inhibitory Quotient (gIQ) predicts virological responce at 24 weeks to TPV-based salvage regimens.
2006-01-01 Bonora S; Gonzalez de Requena D; Calcagno A; Milia MG; D’Avolio A; Sciandra M; Garazzino S; Siccardi M; Sinicco A; Di Perri G.
Unexpected drug-drug interaction between tipranavir/ritonavir (TPV/RTV) and enfuvirtide (T20)
2006-01-01 Gonzalez de Requena D; Calcagno A; Bonora S; Ladetto L; D’Avolio A; Sciandra M; Siccardi M; Bargiacchi O; Sinicco A; Di Perri G.
Clinical pharmacology of nucleoside and nucleotide reverse transcriptase inhibitors
2006-01-01 BONORA S; CALCAGNO A; GONZALEZ DE REQUENA D; BARGIACCHI O; DI PERRI G
Unexpected drug-drug interaction between tipranavir/ritonavir and enfuvirtide
2006-01-01 GONZÁLEZ DE REQUENA D; CALCAGNO A; BONORA S; LADETTO L; D'AVOLIO A; SCIANDRA M; SICCARDI M; BARGIACCHI O; SINICCO A; DI PERRI G
Ritonavir-dependent fluconazole boosting of nelfinavir: a report of three cases
2006-01-01 GARAZZINO S; TETTONI M; CALCAGNO A; D'AVOLIO A; BONORA S; DI PERRI G
Clinically significant drug interaction between tipranavir-ritonavir and phenobarbital in an HIV-infected subject
2007-01-01 BONORA S; CALCAGNO A; FONTANA S; D'AVOLIO A; SICCARDI M; GOBBI F; DI PERRI G
Antiretroviral activity of pegylated interferon alfa-2a in patients co-infected with HIV/hepatitis C virus
2007-01-01 AGUILAR MARUCCO D; VERONESE L; DE REQUENA DG; BONORA S; CALCAGNO A; CAVECCHIA I; SINICCO A; DE ROSA FG; CARITI G; DI PERRI G
PXR 63396C>T is a predictor of boosted and unboosted atazanavir plasma concentrations
2008-01-01 Siccardi M; D'Avolio A; Baietto L; Bonora S; Gatti D; Calcagno A; Oddone V; Simiele M; Sciandra M; Khoo S; Back D; Owen A; Di Perri G.
Plasma concentration of boosted and unboosted Atazanavir are predicted by 63396C>T SNP in the PXR gene
2008-01-01 Siccardi M; D'Avolio A; Baietto L; Calcagno A; Gibbons S; Sciandra M; Bonora S; Khoo S; Back D; Di Perri G; Owen A
Le concentrazioni plasmatriche di ATV boostato ed unboosted correlano con il polimorfismo 63396C>T del pregnane X receptor.
2008-01-01 M. Siccardi; A. D'Avolio; L. Baietto; D. Gatti; A. Calcagno; S. Gibbons; M. Sciandra; S. Bonora; S. Khoo; D. Back; G. Di Perri; A. Owen.
Moxifloxacin for the treatment of HIV-associated tuberculosis in patients with contraindications or intolerance to rifamycins
2008-01-01 Bonora S; Mondo A; Trentini L; Calcagno A; Lucchini A; Di Perri G.
Tipranavir (TPV) genotypic inhibitory quotient predicts virological response at 48 weeks to TPV-based salvage regimens
2008-01-01 Daniel Gonzalez de; Stefano Bonora; Andrea Calcagno; Antonio D'Avolio; Marco Siccardi; Silvia Fontana; Maria Grazia Milia; Mauro Sciandra; Silvia Garazzino; Antonio Di Garbo; Lorena Baietto; Laura Trentini; Giovanni Di Perri
Pharmacokinetic and pharmacodynamic determinants of early virological response to enfuvirtide-based regimens in HIV-positive patients
2008-01-01 Daniel Gonzalez de; Stefano Bonora; Antonella Castagna; Hamid Hasson; Diego Aguilar Marucco; Antonio D'Avolio; Mauro Sciandra; Laura Trentini; Andrea Calcagno; Adriano Lazzarin; Giovanni Di Perri
A population pharmacokinetic model confirms an association between a pregnane-X-receptor (PXR) polymorphism and unboosted atazanavir clearance
2009-01-01 Schipani A; Siccardi M; D'Avolio A; Baietto L; Calcagno A; Tettoni C; Bonora S; Davis G; Khoo S; Back DJ; Di Perri G; Owen A
Natural History of HIV Infection and Evoluton of Antiretroviral Therapy
2009-01-01 G. Di Perri; S. Audagnotto; F. Gobbi; L. Trentini; A Calcagno; S. Bonora
Evaluation of 7 different resistence interpretation algoritms and their derived gentotypic inhibitory quotients for the prediction of 48-week virological response to darunavir-based salvage regimens
2009-01-01 D. Gonzalez de Requena; S. Bonora; A. Calcagno; A. D’Avolio; O. Viganò; L. Baietto; C. Cometto; V. Ghisetti; M. Siccardi; S. Rusconi; G. Di Perri
Effect of Darunavir (DRV) genotypic inhibitory quotient (gIQ) on the virological response to DRV-containing salvage regimens at 24 weeks
2009-01-01 Gonzalez de Requena D; Bonora S; Cometto C; Magnani S; D'Avolio A; Milia M; Vigano' O; Di Garbo A; Calcagno A; Siccardi M; Baietto L; Sciandra M; Rusconi S; Di Perri G.
Is Maraviroc a substrate for SLCO1B1?
2009-01-01 M. Siccardi; A. D’Avolio; S. Nozza; S. Bonora; A. Castagna; L. Baietto; F.R. Stefani; D. Moss; A. Calcagno; M. Sciandra; A. Lazzarin; D. Back; A. Owen; G. Di Perri
Combined effect of SLCO1B1 521T>C, PXR 63396C>T, and ABCB1 3435C>T on the achievement of therapeutic concentrations of unboosted Atazanavir
2009-01-01 M. Siccardi; A. D’Avolio; S. Bonora; L. Baietto; D. Gatti; A. Calcagno; V. Ghisetti; M. Lanzafame; G. Penco; D. Back; A. Owen; G. Di Perri
Intracellular Accumulation of Tipranavir/Ritonavir
2009-01-01 Andrea Calcagno; Daniel Gonzalez De Requena; Antonio D'avolio; Marco Siccardi; Stefano Bonora; Giovanni Di Perri.
| Titolo | Data di pubblicazione | Autore(i) | File |
|---|---|---|---|
| Tipranavir (TPV) genotypic Inhibitory Quotient (gIQ) predicts virological responce at 24 weeks to TPV-based salvage regimens. | 2006 | Bonora S; Gonzalez de Requena D; Calcagno A; Milia MG; D’Avolio A; Sciandra M; Garazzino S; Siccardi M; Sinicco A; Di Perri G. | |
| Unexpected drug-drug interaction between tipranavir/ritonavir (TPV/RTV) and enfuvirtide (T20) | 2006 | Gonzalez de Requena D; Calcagno A; Bonora S; Ladetto L; D’Avolio A; Sciandra M; Siccardi M; Bargiacchi O; Sinicco A; Di Perri G. | |
| Clinical pharmacology of nucleoside and nucleotide reverse transcriptase inhibitors | 2006 | BONORA S; CALCAGNO A; GONZALEZ DE REQUENA D; BARGIACCHI O; DI PERRI G | |
| Unexpected drug-drug interaction between tipranavir/ritonavir and enfuvirtide | 2006 | GONZÁLEZ DE REQUENA D; CALCAGNO A; BONORA S; LADETTO L; D'AVOLIO A; SCIANDRA M; SICCARDI M; BARGIACCHI O; SINICCO A; DI PERRI G | |
| Ritonavir-dependent fluconazole boosting of nelfinavir: a report of three cases | 2006 | GARAZZINO S; TETTONI M; CALCAGNO A; D'AVOLIO A; BONORA S; DI PERRI G | |
| Clinically significant drug interaction between tipranavir-ritonavir and phenobarbital in an HIV-infected subject | 2007 | BONORA S; CALCAGNO A; FONTANA S; D'AVOLIO A; SICCARDI M; GOBBI F; DI PERRI G | |
| Antiretroviral activity of pegylated interferon alfa-2a in patients co-infected with HIV/hepatitis C virus | 2007 | AGUILAR MARUCCO D; VERONESE L; DE REQUENA DG; BONORA S; CALCAGNO A; CAVECCHIA I; SINICCO A; DE ROSA FG; CARITI G; DI PERRI G | |
| PXR 63396C>T is a predictor of boosted and unboosted atazanavir plasma concentrations | 2008 | Siccardi M; D'Avolio A; Baietto L; Bonora S; Gatti D; Calcagno A; Oddone V; Simiele M; Sciandra M; Khoo S; Back D; Owen A; Di Perri G. | |
| Plasma concentration of boosted and unboosted Atazanavir are predicted by 63396C>T SNP in the PXR gene | 2008 | Siccardi M; D'Avolio A; Baietto L; Calcagno A; Gibbons S; Sciandra M; Bonora S; Khoo S; Back D; Di Perri G; Owen A | |
| Le concentrazioni plasmatriche di ATV boostato ed unboosted correlano con il polimorfismo 63396C>T del pregnane X receptor. | 2008 | M. Siccardi; A. D'Avolio; L. Baietto; D. Gatti; A. Calcagno; S. Gibbons; M. Sciandra; S. Bonora; S. Khoo; D. Back; G. Di Perri; A. Owen. | |
| Moxifloxacin for the treatment of HIV-associated tuberculosis in patients with contraindications or intolerance to rifamycins | 2008 | Bonora S; Mondo A; Trentini L; Calcagno A; Lucchini A; Di Perri G. | |
| Tipranavir (TPV) genotypic inhibitory quotient predicts virological response at 48 weeks to TPV-based salvage regimens | 2008 | Daniel Gonzalez de; Stefano Bonora; Andrea Calcagno; Antonio D'Avolio; Marco Siccardi; Silvia Fontana; Maria Grazia Milia; Mauro Sciandra; Silvia Garazzino; Antonio Di Garbo; Lorena Baietto; Laura Trentini; Giovanni Di Perri | |
| Pharmacokinetic and pharmacodynamic determinants of early virological response to enfuvirtide-based regimens in HIV-positive patients | 2008 | Daniel Gonzalez de; Stefano Bonora; Antonella Castagna; Hamid Hasson; Diego Aguilar Marucco; Antonio D'Avolio; Mauro Sciandra; Laura Trentini; Andrea Calcagno; Adriano Lazzarin; Giovanni Di Perri | |
| A population pharmacokinetic model confirms an association between a pregnane-X-receptor (PXR) polymorphism and unboosted atazanavir clearance | 2009 | Schipani A; Siccardi M; D'Avolio A; Baietto L; Calcagno A; Tettoni C; Bonora S; Davis G; Khoo S; Back DJ; Di Perri G; Owen A | |
| Natural History of HIV Infection and Evoluton of Antiretroviral Therapy | 2009 | G. Di Perri; S. Audagnotto; F. Gobbi; L. Trentini; A Calcagno; S. Bonora | |
| Evaluation of 7 different resistence interpretation algoritms and their derived gentotypic inhibitory quotients for the prediction of 48-week virological response to darunavir-based salvage regimens | 2009 | D. Gonzalez de Requena; S. Bonora; A. Calcagno; A. D’Avolio; O. Viganò; L. Baietto; C. Cometto; V. Ghisetti; M. Siccardi; S. Rusconi; G. Di Perri | |
| Effect of Darunavir (DRV) genotypic inhibitory quotient (gIQ) on the virological response to DRV-containing salvage regimens at 24 weeks | 2009 | Gonzalez de Requena D; Bonora S; Cometto C; Magnani S; D'Avolio A; Milia M; Vigano' O; Di Garbo A; Calcagno A; Siccardi M; Baietto L; Sciandra M; Rusconi S; Di Perri G. | |
| Is Maraviroc a substrate for SLCO1B1? | 2009 | M. Siccardi; A. D’Avolio; S. Nozza; S. Bonora; A. Castagna; L. Baietto; F.R. Stefani; D. Moss; A. Calcagno; M. Sciandra; A. Lazzarin; D. Back; A. Owen; G. Di Perri | |
| Combined effect of SLCO1B1 521T>C, PXR 63396C>T, and ABCB1 3435C>T on the achievement of therapeutic concentrations of unboosted Atazanavir | 2009 | M. Siccardi; A. D’Avolio; S. Bonora; L. Baietto; D. Gatti; A. Calcagno; V. Ghisetti; M. Lanzafame; G. Penco; D. Back; A. Owen; G. Di Perri | |
| Intracellular Accumulation of Tipranavir/Ritonavir | 2009 | Andrea Calcagno; Daniel Gonzalez De Requena; Antonio D'avolio; Marco Siccardi; Stefano Bonora; Giovanni Di Perri. |
Legenda icone
- file ad accesso aperto
- file disponibili sulla rete interna
- file disponibili agli utenti autorizzati
- file disponibili solo agli amministratori
- file sotto embargo
- nessun file disponibile